Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BIntech Biopharm Ltd. 〉low-alcohol formulation (iLEF) platform

low-alcohol formulation (iLEF) platform

low-alcohol formulation (iLEF) platform

Request for Collaboration
Overview
Intech Biopharm focus on new dosage, new combination, new delivery and high barrier generic drug development and manufacturing for respiratory therapy area.  We are currently one of the leading companies, and the only one in Taiwan, that can provide and manufacture high barrier obstructive airway diseases drug and our competitive advantage are as follow:
 
http://www.intechbiopharm.com/en/images/smlc.png iLEF platform: It has a low-alcohol formulation (iLEF) platform with advantages of less excipient used, good content uniformity, good stability etc. Patent has been granted for manufacturing method by Intellectual Property Office (TIPO) of Taiwan and Singapore. The patent number is I399202 and SG2014011597B respectively.
 
http://www.intechbiopharm.com/en/images/smlc.png HFA MDI platform: Intech Biopharm possesses specialized technology on manufacturing HFA metered dose inhaler (HFA MDI). Based on this technology (iLEF platform), drug suspension is released in tiny particles through actuators (mouthpiece) and later inhaled into the lung, by which local inflammation or other relevant diseases can be treated.
 
http://www.intechbiopharm.com/en/images/smlc.png DPI platform: Intech Biopharm have its own formulation knowledge and self development device for DPI inhalation product.
 
http://www.intechbiopharm.com/en/images/smlc.png Analytical facility: Not only the analytical equipment for traditional drug analysis, Intech also invest the equipment for analysis equipment for MDI and DPI products.
 
http://www.intechbiopharm.com/en/images/smlc.png Qualified Manufacturing site: the manufacturing facilities in Hsinchu is at the high level as PIC/S and US FDA GMP standard
 
http://www.intechbiopharm.com/en/images/smlc.png Regulatory Affairs and Clinical: Intech Biopharm already got approvals in Taiwan and some countries in the great China and is going to submit to EU and US. We are experienced in designing and executing cost-effective global scope clinical study and currently one of the study is proceeding
Patent Portfolio
Collaboration Options
We are targeting on the repertory diseases drug development and manufacturing with our specialty of MDI, DPI and Nasal spray. We are looking for a partner can promote our developed product to global market. In the meantime, take advantage of our diversified specialty we also support co-development or contract manufacture business (OEM & ODM) for high barrier generic product and new drug development.
More Information
People who like this also like
  • Clinical & Regulatory ExpertiseClinical & Regulatory Expertise
  • PHDC-02PHDC-02
  • JHL1178 Ramucirumab BiosimilarJHL1178 Ramucirumab Biosimilar
  • NGS-SMSEQ®NGS-SMSEQ®
  • Homogeneous antibody drugs (CHO-H01, H02, H03)Homogeneous antibody drugs (CHO-H01, H02, H03)
  • JHL1255 Ustekinumab BiosimilarJHL1255 Ustekinumab Biosimilar
  • The Most Professional AccreditationThe Most Professional Accreditation
  • Rexis®Rexis®
  • Pilot scale up development and manufacturingPilot scale up development and manufacturing
  • Implant SystemImplant System